DA-LIANG OULin, Yu-YangYu-YangLinCHIA-LANG HSULin, Yin-YaoYin-YaoLinChen, Chia-WeiChia-WeiChenYu, Jhang-SianJhang-SianYuSHI-CHUEN MIAWPING-NING HSUANN-LII CHENGCHIUN HSU2020-08-142020-08-142019-052235-1795https://scholars.lib.ntu.edu.tw/handle/123456789/512837Anti-programmed cell death-1(anti-PD1) treatment has shown promising antitumor efficacy in patients with advanced hepatocellular carcinoma (HCC). This study sought to explore the functional significance of programmed death ligand-1 (PD-L1) expression in tumor cells in the tumor microenvironment.animationAnti-programmed cell death-1; CD8+ T cells; Immune checkpoint inhibitor; Sorafenib; Tumor-infiltrating lymphocytes[SDGs]SDG3antineoplastic agent; programmed death 1 ligand 1; rmp 114; sorafenib; unclassified drug; animal cell; animal experiment; animal model; Article; cancer immunotherapy; cancer transplantation; cell growth; cell proliferation; colony formation; controlled study; echography; flow cytometry; human; human cell; in vitro study; liver cancer cell line; liver cell carcinoma; liver transplantation; lymphocyte function; mouse; nonhuman; priority journal; protein expression; tumor microenvironmentjournal article10.1159/000489318311921532-s2.0-85049433648WOS:000468939100002